[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fibroblast-activation-protein-inhibitor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fibroblast-activation-protein-inhibitor":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,74,105,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100576806","phase-2-the-diagnostic-accuracy-and-clinical-value-of-fapi-pet-in-pleural-mesothelioma-100576806",false,"NCT06790082","The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma","FAPI PET in Pleural Mesothelioma: The Diagnostic Accuracy and Clinical Value of FAPI PET at Diagnosis, Primary Staging, and the Feasibility of FAPI PET for Response Evaluation","FAPI-PM","Inclusion Criteria:\n\n* Patients with pleural lesions suspicious of pleural mesothelioma and referred to pleural biopsy.\n* Undergone\u002Fundergoing FDG PET\u002FCT as part of the diagnostic workup of a suspicious PM lesion.\n* Considered physically and mentally able to participate in the research project.\n* Understands the study subject information and able to consent to project participation.\n* 18-years or older\n\nExclusion Criteria:\n\n* Patients with an imminent need for surgery or in an emergency\n* Known concurrent other malignancy with active treatment within the last 1 year; non-melanoma skin cancer and cervical cancer in situ are exempt.\n* Pregnant or breastfeeding women.\n* Fertile women (women of childbearing potential) who could - theoretically - be pregnant (i.e., unknown pregnancy status).\n\nFertile women will be tested for pregnancy (by urine humane choriogonadotropin (HCG) or serum HCG) within 48h before FAPI PET\u002FCTs, both at primary staging and restaging. Study subjects can participate in the study if the pregnancy test is negative (i.e., not pregnant).\n\n* Subjects unable to undergo PET\u002FCT: e.g., weighing more than 180 kg (weight limit scanner), unable to fit within the imaging gantry, inability to remain still for the duration of the examination, or with known severe claustrophobia unresponsive to oral anxiolytics or severe fear of needles.\n* Subjects with any medical condition or other circumstances that, in the opinion of the Investigator, would significantly decrease the reliability of data, achievement of study objectives or completing the study.\n* History of allergic reactions \u002F hypersensitivity attributed to \\[18F\\]FDG or FAPI-tracers.","ALL","18 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Seventy (N=70) patients with suspected pleural mesothelioma (PM) lesions referred to pleural biopsy will be recruited, and undergo an additional FAPI PET\u002FCT at primary staging.\n\nThe FAPI PET\u002FCT results will be compared to conventional imaging (including FDG PET\u002FCT). The diagnostic accuracy will be determined with histopathology as reference standard.\n\nFor patients undergoing anticancer treatment (chemotherapy, immunotherapy, other treatment), an additional FAPI PET\u002FCT and an additional FDG PET\u002FCT will be conducted after the study subjects have completed 2-3 series of anticancer treatment. The feasabilitiy of FAPI PET\u002FCT in response evaluation will be investigated.\n\nAll study specific analyzes will be blinded and will not influence the patient management \u002F treatment.",[27,28,29,30,31],"Pleural Mesothelioma","Pleural Diseases","Cancer","FAPI","Fibroblast Activation Protein Inhibitor",[30,33,34,27,35],"68Ga-FAPI-46","PET\u002FCT","FDG PET\u002FCT","RECRUITING","2025-07-01",{"date":39,"type":40},"2025-07-03","ACTUAL",{"date":42,"type":40},"2025-01-29",{"date":44,"type":21},"2037-04-30",{"name":46,"class":47},"Aalborg University Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":48},"100441881","68ga-fapi-petct-in-malignant-tumors-100441881","NCT05034146","68Ga-FAPI PET\u002FCT in Malignant Tumors","The Diagnostic Efficiency of 68Ga-FAPI PET\u002FCT in Malignant Tumors","Inclusion Criteria:\n\nVolunteering to participate in clinical trial and sign an informed consent form Patients with suspected or confirmed malignant tumor\n\nExclusion Criteria:\n\nFemale patients plan to become pregnant within 6 months Pregnant and lactating women Patients are allergic to multiple drugs including test drug Patients have participated in other clinical trials in the past one month",true,"88 Years",{"count":59,"type":21},500,[61],"NA","Fibroblast-activation protein (FAP) is a type Ⅱ transmembrane serine protease and is overexpressed in cancer-associated fibroblasts (CAFs). CAFs are the predominant component in the stroma of epithelial neoplasms. FAP can be detected in various of malignant neoplasms and is associated to tumor cell migration, invasion, and angiogenesis. Recently, a novel molecular probe, gallium 68-labelled FAP inhibitor (68Ga-FAPI), has been developed and used for visualization of tumor stroma by targeting FAP. Recent studies show favorable diagnosis efficiency in a variety of tumors, especially in gastrointestinal cancer, but the previous studies were all small-sample data or case reports. Therefore, further large-size research is necessary to confirm the advantages of 68Ga-FAPI in various of malignant tumors.",[31,34,64],"Malignant Neoplasm","2025-05-31",{"date":67,"type":40},"2025-06-05",{"date":69,"type":40},"2021-02-23",{"date":71,"type":21},"2025-12-31",{"name":73,"class":47},"Zhongnan Hospital",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":56,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100586138","from-inflammation-to-remodelling-towards-personalized-diagnosis-in-post-acute-sequelae-of-covid-19-100586138","NCT06911476","From Inflammation to Remodelling Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19","From Inflammation Biomarkers to Remoddeling (FAPI PET\u002FCT) Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19","LIBERATE","Inclusion Criteria:\n\n\\- Self-reported complaints of dyspnea or fatigue \\> 3 months after SARS-CoV-2 infection confirmed with PCR, serology test or COVID-19 Reporting and Data System (CO-RADS) score 4\u002F5.\n\nExclusion Criteria:\n\n* Inability or unwilling to give informed consent.\n* History of claustrophobia or feeling of inability to tolerate supine position for the PET\u002FCT scans.\n* Individuals who are pregnant or currently breastfeeding are not eligible to participate","20 Years",{"count":84,"type":21},60,"OBSERVATIONAL","Rationale: The diagnosis and pathogenesis of long COVID remains unknown. We have previously shown that \\[68Ga\\]FAPI Positron Emission Tomography-Computed Tomography (PET\u002FCT) imaging shows potential for diagnosis and molecular understanding of this syndrome. We have previously shown that fibroblast activation protein (FAP) can be imaged in the lung, muscle and nasopharynx of long COVID patients (with dyspnea and fatigue). However, these preliminary data are derived from a selective group of patients with long COVID after critical COVID-19. We aim to explore the generalizability of these findings in patients with long COVID with dyspnea and fatigue, irrespective of the severity of their acute SARS-CoV-2 infection.\n\nPrimary objective: To assess if pulmonary fibroblast activity, measured by \\[68Ga\\]FAPI-46 PET\u002FCT, is higher in patients with current long COVID dyspnea and fatigue compared to patients with resolved complaints.\n\nStudy design: This is a ZonMw funded single centre prospective observational cohort study of long COVID-19 patients with dyspnea and fatigue.\n\nStudy population: We will recruit 60 adult long COVID patients (aged \\>20 years) of which 30 have complaints of dyspnea and fatigue and compare them to 30 patients with resolved complaints and healthy controls.\n\nMain study parameters\u002Fendpoints: The primary endpoint is FAP expression in the lung measured by \\[68Ga\\]FAPI-46 PET\u002FCT. Secondary endpoints are the expression of FAP in other tissues (muscle) and the relation between FAP and inflammation and remodelling biomarkers in various biological samples (e.g. serum\u002Fnasal epithelium).\n\nStudy procedures: In a single visit day the following data and samples will be collected: questionnaires, a lung function test, 6-minute walking test, blood samples, nose swabs, \\[68Ga\\]FAPI PET\u002FCT scan and HRCT scan. When increased \\[68Ga\\]FAPI uptake is measured in the muscles a muscle biopsy will be performed as well.",[88,89,90,91,30,92,31,93,94],"PASC Post Acute Sequelae of COVID 19","Long COVID","Long Covid-19","PASC","FAP","Fibroblast","Restrictive Lung Disease","NOT_YET_RECRUITING","2025-04-03",{"date":98,"type":40},"2025-04-04",{"date":100,"type":21},"2025-05",{"date":102,"type":21},"2025-12",{"name":104,"class":47},"University Medical Center Groningen",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":48},"100562523","phase-2-unravelling-intestinal-fibrosis-in-ulcerative-colitis-100562523","NCT06604273","Unravelling Intestinal Fibrosis in Ulcerative Colitis","INTERACT","Inclusion Criteria:\n\n* Adults with confirmed diagnosis of UC - Group 1 criterion: ≥18 years of age regardless of gender\n* Group 2 criterion: ≥30 years of age for males and ≥40 years of age for females\n* Active disease confirmed by endoscopy (endoscopic Mayo score ≥ 2)\n* Indication to start treatment with filgotinib\n\nAND one of the following criteria:\n\n* Active disease confirmed by intestinal ultrasound (BWT \\> 3 mm in at least one bowel segment and at least one other pathological IUS parameter) or\n* Increased CRP (\\>5 mg\u002FL) and\u002For fecal calprotectin levels (\\>250 mg\u002Fkg)\n\nExclusion Criteria:\n\n* Pregnancy\n* Unable to provide informed consent\n* Colorectal carcinoma or high-grade dysplasia",{"count":113,"type":21},10,[24,115],"PHASE3","The main objectives are: (i) to identify candidate fibrotic cellular pathways in UC patients treated with a JAK inhibitor filgotinib), and (ii) to detect and monitor in vivo fibrosis in UC patients using FAPi-PET\u002FCT imaging",[118,119,31],"Ulcerative Colitis (UC)","Inflammatory Bowel Disease (IBD)",[121,30,122,123,124],"PET CT","IBD","Ulcerative colitis","Filgotinib","2024-09-17",{"date":127,"type":40},"2024-09-19",{"date":129,"type":40},"2024-04-03",{"date":131,"type":21},"2026-04-03",{"name":133,"class":47},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":145,"conditions":146,"keywords":150,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":48},"100537388","68ga-tcr-fapi-petct-guided-precision-surgery-for-mtc-100537388","NCT06277180","68Ga-TCR-FAPI PET\u002FCT Guided Precision Surgery for MTC","Evaluating the Clinical Value of 68Ga-TCR-FAPI PET\u002FCT to Guide the Surgical Treatment for Medullary Thyroid Carcinoma (MTC)","Inclusion Criteria:\n\n* Age between 18 and 75 years；\n* Diagnosed with MTC and have surgical indication based on preliminary evaluation; the tumor may be newly diagnosed or previously treated;\n* Expected survival of at least 12 weeks;\n* No major organ dysfunction (heart, lung, liver, kidney and other major organ include), acute or life-threatening status of infection;\n* Be willing and able to understand the research content and provide written informed consent\u002Fassent for the trial.\n\nExclusion Criteria:\n\n* Have a history of imaging agent allergies;\n* Does not meet the PET-CT scan sedation requirements, or has contraindications for PET-CT examination;\n* Be pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial;\n* No surgical indication (i.e., no measurable disease, unresectable disease, or significant present of distant metastasis), refusing surgery or 68Ga-TCR-FAPI PET\u002FCT-guided surgery.","75 Years",{"count":143,"type":21},50,[61],"This is a phase II clinical trial to evaluate the capability of 68Ga-labeled targeted covalent radiopharmaceutical (TCR) fibroblast activation protein inhibitor (FAPI) PET\u002FCT to guide the surgical treatment of medullary thyroid carcinoma (MTC). The surgical extent of MTC is determined based on the lesion range revealed by 68Ga-TCR-FAPI PET\u002FCT, with the main endpoint being 1-month post-surgical calcitonin level.",[147,148,31,149],"Medullary Thyroid Cancer","Prositron Emission Tomography","Surgery",[147,148,31,149],"2024-02-18",{"date":153,"type":40},"2024-02-26",{"date":155,"type":40},"2023-10-01",{"date":157,"type":21},"2027-12-31",{"name":159,"class":47},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"]